InspireMD Future Growth
Future criteria checks 2/6
InspireMD is forecast to grow revenue at 58.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 12.9% |
Revenue growth rate | 58.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation
Jan 11We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully
Jan 27We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate
Oct 05InspireMD: Revolutionizing The Field Of Vascular Stenting
Sep 20Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares
Feb 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 48 | N/A | N/A | N/A | 1 |
12/31/2026 | 27 | N/A | N/A | N/A | 2 |
12/31/2025 | 10 | N/A | N/A | N/A | 2 |
12/31/2024 | 7 | N/A | N/A | N/A | 2 |
9/30/2024 | 7 | -28 | -21 | -19 | N/A |
6/30/2024 | 7 | -26 | -19 | -18 | N/A |
3/31/2024 | 6 | -23 | -17 | -17 | N/A |
12/31/2023 | 6 | -20 | -17 | -16 | N/A |
9/30/2023 | 5 | -19 | -16 | -15 | N/A |
6/30/2023 | 5 | -19 | -17 | -16 | N/A |
3/31/2023 | 5 | -18 | -17 | -16 | N/A |
12/31/2022 | 5 | -18 | -16 | -16 | N/A |
9/30/2022 | 6 | -18 | -16 | -15 | N/A |
6/30/2022 | 5 | -17 | -15 | -14 | N/A |
3/31/2022 | 5 | -16 | -14 | -14 | N/A |
12/31/2021 | 4 | -15 | -14 | -13 | N/A |
9/30/2021 | 3 | -15 | -13 | -13 | N/A |
6/30/2021 | 3 | -13 | -12 | -11 | N/A |
3/31/2021 | 2 | -12 | -10 | -10 | N/A |
12/31/2020 | 2 | -11 | -9 | -9 | N/A |
9/30/2020 | 3 | -9 | -9 | -8 | N/A |
6/30/2020 | 3 | -9 | -7 | -7 | N/A |
3/31/2020 | 4 | -9 | -9 | -9 | N/A |
12/31/2019 | 4 | -10 | -10 | -10 | N/A |
9/30/2019 | 4 | -10 | -10 | -10 | N/A |
6/30/2019 | 3 | -10 | -10 | -10 | N/A |
3/31/2019 | 3 | -8 | -9 | -9 | N/A |
12/31/2018 | 4 | -8 | -8 | -8 | N/A |
9/30/2018 | 4 | -11 | -8 | -8 | N/A |
6/30/2018 | 4 | -11 | N/A | -8 | N/A |
3/31/2018 | 3 | -12 | N/A | -7 | N/A |
12/31/2017 | 3 | -13 | N/A | -8 | N/A |
9/30/2017 | 2 | -10 | N/A | -8 | N/A |
6/30/2017 | 2 | -10 | N/A | -9 | N/A |
3/31/2017 | 2 | -9 | N/A | -8 | N/A |
12/31/2016 | 2 | -8 | N/A | -7 | N/A |
9/30/2016 | 2 | -9 | N/A | -8 | N/A |
6/30/2016 | 2 | -11 | N/A | -7 | N/A |
3/31/2016 | 2 | -13 | N/A | -9 | N/A |
12/31/2015 | 2 | -16 | N/A | -12 | N/A |
9/30/2015 | 3 | -18 | N/A | -14 | N/A |
6/30/2015 | 2 | -21 | N/A | -18 | N/A |
3/31/2015 | 2 | -24 | N/A | -20 | N/A |
12/31/2014 | 3 | -25 | N/A | -19 | N/A |
9/30/2014 | 4 | -26 | N/A | -18 | N/A |
6/30/2014 | 5 | -23 | N/A | -15 | N/A |
3/31/2014 | 6 | -30 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NSPR's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if NSPR's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if NSPR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NSPR's revenue (58.1% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: NSPR's revenue (58.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NSPR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 02:39 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InspireMD, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Raymond Myers | Benchmark Company |
Keay Nakae | Chardan Capital Markets, LLC |
Jose Teodorico De Jesus Haresco | JMP Securities |